To screen ETFs by asset class, performance, yield and more, check out the
Author Following Options:
Follow this author
See their articles on your Seeking Alpha homepage and in your feed.
Real-time alerts on this author
Get their new articles emailed to you as they are published.
Daily digest on all my authors
Get all your favorite authors’ new articles emailed to you in one daily digest.
View as an RSS Feed
View Laura-Mae Britton's Comments
New Cancer Targets And Big Partnerships May Be Driving Huge Epizyme Valuation
Thanks for your feedback, and great question!
More often than not, companies will not release sales data from drugs that aren’t driving huge revenues so in the case of Zolina, there isn’t much data available data from Merck. For Istodax (romidepsin), sales increased more than three-fold from $15.8 million in 2010 at the product’s debut, to $50 million in 2012. Some of the rapid increases in sales can be attributed to the drug’s accelerated approval in 2011 to treat patients with peripheral T-cell lymphoma. However I should just mention that although HDACi’s and HMTi’s both target “epigenetic mechanisms”, their pathways are quite different and therefore the success or failure of Zolina and Istodax does not necessarily translate to Epizyme’s projected sale values.
One other interesting tidbit is that Gloucester Pharmaceuticals developed Istodax to FDA approval for the first indication, second-line treatment for CTCL but was then acquired by Celgene for $340 million upfront and $300 million in future milestones payments.
Sep 9 04:09 PM
Link to Comment
Xignite quote data
© 2014 Seeking Alpha